Search
Estradiol
go.drugbank.com/drugs/DB00783ApprovedInvestigationalVet approvedBecause it has a low oral bioavailability on its own, estradiol is commonly formulated with an ester side-chain.
Indalpine
go.drugbank.com/drugs/DB08953ApprovedWithdrawnHowever, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market. … It was initially marketed by Pharmuka.
Etofamide
go.drugbank.com/drugs/DB13258ApprovedEtofamide is used as an antiamoebic agent. Etofamide, under the brand name Kitnos, was marketed in Brazil by Pfizer but has been discontinued [L5617].
Alverine
go.drugbank.com/drugs/DB01616ApprovedInvestigationalWithdrawnIt can also be used to help relieve period pain.
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]
Progesterone
go.drugbank.com/drugs/DB00396ApprovedInvestigationalVet approvedA low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss [A175609].
Protein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalProtein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. … It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC).
Daprodustat
go.drugbank.com/drugs/DB11682ApprovedInvestigationalOctober 2022, the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) supported that the benefit of treatment with daprodustat outweighs the risks for adult dialysis patients with anemia of CKD but … [L43857] On February 1, 2023, daprodustat was fully approved by the FDA as the first oral treatment for anemia caused by chronic kidney disease in patients on dialysis.
Famtozinameran
go.drugbank.com/drugs/DB17088ApprovedInvestigational[L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigational[A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]